[1]
|
Webb, P.M. and Jordan, S.J. (2017) Epidemiology of Epithelial Ovarian Cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 41, 3-14. https://doi.org/10.1016/j.bpobgyn.2016.08.006
|
[2]
|
Narod, S. (2016) Can Advanced-Stage Ovarian Cancer Be Cured? Nature Reviews Clinical Oncology, 13, 255-261.
https://doi.org/10.1038/nrclinonc.2015.224
|
[3]
|
Choi, E.J., Seo, E.J., Kim, D.K., Lee, S.I., Kwon, Y.W., Jang, I.H., et al. (2016) FOXP1 Functions as an Oncogene in Promoting Cancer Stem Cell-Like Characteristics in Ovarian Cancer Cells. Oncotarget, 7, 3506-3519.
https://doi.org/10.18632/oncotarget.6510
|
[4]
|
Katoh, M., Igarashi, M., Fukuda, H., Nakagama, H. and Katoh, M. (2013) Cancer Genetics and Genomics of Human FOX Family Genes. Cancer Letters, 328, 198-206. https://doi.org/10.1016/j.canlet.2012.09.017
|
[5]
|
Koon, H.B., Ippolito, G.C., Banham, A.H. and Tucker, P.W. (2007) FOXP1: A Potential Therapeutic Target in Cancer. Expert Opinion on Therapeutic Targets, 11, 955-965. https://doi.org/10.1517/14728222.11.7.955
|
[6]
|
Kim, J.H., Hwang, J., Jung, J.H., Lee, H.-J., Lee, D.Y. and Kim, S.-H. (2019) Molecular Networks of FOXP Family: Dual Biologic Functions, Interplay with Other Molecules and Clinical Implications in Cancer Progression. Molecular Cancer, 18, Article No. 180. https://doi.org/10.1186/s12943-019-1110-3
|
[7]
|
Hu, Z., Zhu, L., Gao, J., Cai, M., Tan, M., Liu, J., et al. (2015) Expression of FOXP1 in Epithelial Ovarian Cancer (EOC) and Its Correlation with Chemotherapy Resistance and Prognosis. Tumor Biology, 36, 7269-7275.
https://doi.org/10.1007/s13277-015-3383-5
|
[8]
|
Hu, Z., Cai, M., Zhang, Y., Tao, L. and Guo, R. (2020) miR-29c-3p Inhibits Autophagy and Cisplatin Resistance in Ovarian Cancer by Regulating FOXP1/ATG14 Pathway. Cell Cycle, 19, 193-206.
https://doi.org/10.1080/15384101.2019.1704537
|
[9]
|
Ricci, F., Fratelli, M., Guffanti, F., Porcu, L., Spriano, F., Dell’Anna, T., et al. (2017) Patient-Derived Ovarian Cancer Xenografts Re-Growing after a Cisplatinum Treatment Are Less Responsive to a Second Drug Rechallenge: A New Experimental Setting to Study Response to Therapy. Oncotarget, 8, 7741-7451.
https://doi.org/10.18632/oncotarget.7465
|
[10]
|
Nameki, R., Chang, H., Reddy, J., Corona, R.I. and Lawrenson, K. (2021) Transcription Factors in Epithelial Ovarian Cancer: Histotype-Specific Drivers and Novel Therapeutic Targets. Pharmacology & Therapeutics, 220, Article ID: 107722. https://doi.org/10.1016/j.pharmthera.2020.107722
|
[11]
|
Li, H., Liang, J., Qin, F. and Zhai, Y. (2018) MiR-374b-5p-FOXP1 Feedback Loop Regulates Cell Migration, Epithelial-Mesenchymal Transition and Chemosensitivity in Ovarian Cancer. Biochemical and Biophysical Research Communications, 505, 554-560. https://doi.org/10.1016/j.bbrc.2018.09.161
|
[12]
|
Liao, J., Qian, F., Tchabo, N., Mhawech-Fauceglia, P., Beck, A., Qian, Z., et al. (2014) Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. PLoS ONE, 9, e84941. https://doi.org/10.1371/journal.pone.0084941
|
[13]
|
Zhu, L., Hu, Z., Liu, J. Gao, J. and Lin, B. (2015) Gene Expression Profile Analysis Identifies Metastasis and Chemoresistance-Associated Genes in Epithelial Ovarian Carcinoma Cells. Medical Oncology, 32, Article No. 426.
https://doi.org/10.1007/s12032-014-0426-5
|
[14]
|
Roy, L. and Cowden Dahl, K.D. (2018) Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer? Cancers (Basel), 10, Article No. 241. https://doi.org/10.20944/preprints201806.0262.v1
|
[15]
|
Giatromanolaki, A., Koukourakis, M.I., Sivridis, E., Gatter, K.C., Harris, A.L. and Banham, A.H. (2006) Loss of Expression and Nuclear/Cytoplasmic Localization of the FOXP1 Forkhead Transcription Factor Are Common Events in Early Endometrial Cancer: Relationship with Estrogen Receptors and HIF-1alpha Expression. Modern Pathology, 19, 9-16. https://doi.org/10.1038/modpathol.3800494
|
[16]
|
Bates, G.J., Fox, S.B., Han, C., Launchbury, R., Leek, R.D., Harris, A.L., et al. (2008) Expression of the Forkhead Transcription Factor FOXP1 Is Associated with That of Estrogen Receptor-Beta in Primary Invasive Breast Carcinomas. Breast Cancer Research and Treatment, 111, 453-459. https://doi.org/10.1007/s10549-007-9812-4
|
[17]
|
Rayoo, M., Yan M., Takano, E.A., Bates, G.J., Brown, P.J., Banham, A.H., et al. (2009) Expression of the Forkhead Box Transcription Factor FOXP1 Is Associated with Oestrogen Receptor Alpha, Oestrogen Receptor Beta and Improved Survival in Familial Breast Cancers. Journal of Clinical Pathology, 62, 896-902.
https://doi.org/10.1136/jcp.2009.065169
|
[18]
|
Sethi, S., Sethi, S. and Bluth, M.H. (2018) Clinical Implication of MicroRNAs in Molecular Pathology: An Update for 2018. Clinics in Laboratory Medicine, 38, 237-251. https://doi.org/10.1016/j.cll.2018.02.003
|
[19]
|
Qian, D., Chen, K., Deng, H., Rao, H., Huang, H., Liao, Y., et al. (2015) MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-Cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clinical Cancer Research, 21, 4881-4891. https://doi.org/10.1158/1078-0432.CCR-14-2947
|
[20]
|
Qin, W., Xie, W., He, Q., Sun, T., Meng, C., Yang, K., et al. (2018) MicroRNA-152 Inhibits Ovarian Cancer Cell Proliferation and Migration and May Infer Improved Outcomes in Ovarian Cancer through Targeting FOXP1. Experimental and Therapeutic Medicine, 15, 1672-1679. https://doi.org/10.3892/etm.2017.5529
|
[21]
|
Grunewald, T. and Ledermann, J.A. (2017) Targeted Therapies for Ovarian Cancer. Best Practice & Research Clinical Obstetrics & Gynaecology, 41, 139-152. https://doi.org/10.1016/j.bpobgyn.2016.12.001
|
[22]
|
Modugno, F. and Edwards, R.P. (2012) Ovarian Cancer: Prevention, Detection, and Treatment of the Disease and Its Recurrence. Molecular Mechanisms and Personalized Medicine Meeting Report. International Journal of Gynecologic Cancer, 22, S45-S57. https://doi.org/10.1097/IGC.0b013e31826bd1f2
|